Lopes A, Daras V, Cross P A, Robertson G, Beynon G, Monaghan J M
Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, England.
Cancer. 1994 Jul 1;74(1):90-2. doi: 10.1002/1097-0142(19940701)74:1<90::aid-cncr2820740116>3.0.co;2-0.
Thrombocytosis (a platelet count > 400 x 10(9)/l) is found frequently in association with malignant disease and recently has been suggested to be a poor prognostic indicator in patients with cervical cancer. The authors decided to see if these findings could be verified.
The pretreatment platelet counts of 643 women treated for cervical cancer between 1983 and 1992 were reviewed and correlated to each patient's age, stage of disease, histologic type, node status (when available), and outcome. Differences between groups were analyzed using the chi 2 test, and survival was compared using the log rank test on Kaplan-Meier life tables.
The 5-year survival rate for patients with thrombocytosis was 57.1%, which was significantly worse than the 76.5% for those with normal platelet counts (P < 0.01). When adjusted for stage of disease, however, thrombocytosis failed to have a significant effect on patient survival. There was also no relation between thrombocytosis and the incidence of positive lymph nodes.
Thrombocytosis was not found to be an independent prognostic factor in patients with carcinoma of the cervix in this series of 643 patients.
血小板增多症（血小板计数>400×10⁹/L）常与恶性疾病相关，最近有研究表明其在宫颈癌患者中是一个不良预后指标。作者决定验证这些发现。
回顾了1983年至1992年间接受宫颈癌治疗的643名女性的治疗前血小板计数，并将其与每位患者的年龄、疾病分期、组织学类型、淋巴结状态（如有）及预后相关联。使用卡方检验分析组间差异，使用Kaplan-Meier生存表上的对数秩检验比较生存率。
血小板增多症患者的5年生存率为57.1%，显著低于血小板计数正常患者的76.5%（P<0.01）。然而，在根据疾病分期进行调整后，血小板增多症对患者生存率没有显著影响。血小板增多症与阳性淋巴结的发生率之间也没有关系。
在这643例患者系列中，未发现血小板增多症是宫颈癌患者的独立预后因素。
